GSK3B and colitis: However, single studies reported increased GSK3β activity in colitis-limiting approaches, e.g., increased p-GSK3β-Tyr216 levels following injection of the peroxisome proliferator-activated receptor (PPAR-)γ modulator GED-0507-34 Levo [111].